Nasolacrimal Duct Obstruction Secondary to Radioactive Iodine-131 Therapy for Differentiated Thyroid Cancer

Deterministic effects of medical exposure to ionising radiation can be associated with both the effectiveness of treatment and adverse drug reactions to it. The latter may drastically deteriorate the quality of life of a patient after radionuclide therapy. In addition, the regulations of the Russian Federation require indicating the effective dose of radiation as a measure of damage (risk), but the presence of a deterministic effect in individual organs and tissues complicates monitoring and recording patient exposure doses. The aim of the study was to investigate the effect of radiopharmaceuticals containing ¹³¹I on the development of secondary nasolacrimal duct obstruction (NLDO). Materials and methods: the study of secondary NLDO predictors analysed medical history data, post-therapy head-and-neck scintigrams, and methods to prepare patients for treatment. It involved sodium iodide, ¹³¹I, formulated as a solution (marketing authorisation number: FS-002065) by the FSUE Federal Center of Nuclear Medicine Projects Design and Development of the FMBA of Russia. Results: the authors unambiguously localised the lacrimal ducts in post-therapy ¹³¹I scintigrams of the head and neck and quantified ¹³¹I uptake ratios for the lacrimal duct area. Also, they identified a set of NLDO predictors: the age of a patient, the administered activity, the administration of recombinant human thyroid-stimulating hormone, the ¹³¹I uptake ratio, etc. The article describes a method for identifying the groups at risk of NLDO following radioiodine therapy for differentiated thyroid cancer. Conclusions: secondary NLDO is a deterministic effect of ¹³¹I exposure. The authors have developed a new method for predicting secondary NLDO by a combination of the patient’s individual parameters and treatment plan; the identified predictors help to personalise radioiodine therapy. The authors suggest the following: to include information on secondary NLDO as a complication of therapy to the SmPC section on undesirable effects; to develop approaches to secondary NLDO prevention; and to improve the algorithms for reporting adverse events in case of delayed manifestation and those for following patients up in the medical organisations having administered the radiopharmaceutical or in other medical organisations being applied to for medical care afterwards.

1. Luster M, Pfestroff A, Hanscheid H, Verburg FA. Radioiodine therapy. Semin Nucl Med. 2017;47(2):126–34. https://doi.org/10.1053/j.semnuclmed.2016.10.002

2. Rumyantsev PO, Korenev SV. The history of radioiodine therapy beginnings. Klinicheskaya i eksperimentalnaya tireoidologiya = Clinical and Experimental Thyroidology. 2015;11(4):51–5 (In Russ.) https://doi.org/10.14341/ket2015451-55

3. Dedov II, Rumyantsev PO, Nizhegorodova KS, Slashchuk KYu, Yasyuchenya VS, Sheremeta MS, et al. Recombinant human thyrotropin in radioiodine diagnostics and radioiodine ablation of patients with well-differentiated thyroid cancer: the first experience in Russia. Endokrinnaya khirurgiya = Endocrine Surgery. 2018;12(3):128–39 (In Russ.) https://doi.org/10.14341/serg9806

4. Jeong SY, Kim HW, Lee SW, Ahn BC, Lee J. Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerostomia symptoms. Thyroid. 2013;23(5):609–16. https://doi.org/10.1089/thy.2012.0106

5. Kim JW, Kim JM, Choi ME, Kim SK, Kim YM, Choi JS. Does salivary function decrease in proportion to radioiodine dose? Laryngoscope. 2020;130(9):2173–8. https://doi.org/10.1002/lary.28342

6. Klein Hesselink EN, Brouwers AH, de Jong JR, van der Horst-Schrivers AN, Coppes RP, Lefrandt JD, et al. Effects of radioiodine treatment on salivary gland function in patients with differentiated thyroid carcinoma: a prospective study. J Nucl Med. 2016;57(11):1685–91. https://doi.org/10.2967/jnumed.115.169888

7. Walter MA, Turtschi CP, Schindler C, Minnig P, Muller-Brand J, Muller B. The dental safety profile of high-dose radioiodine therapy for thyroid cancer: long-term results of a longitudinal cohort study. J Nucl Med. 2007;48(10):1620–5. https://doi.org/10.2967/jnumed.107.042192

8. Malanchuk VA, Kopchak AV, Kovalenko VA. Clinical manifestations of salivary gland dysfunction of patients who received radioactive iodine therapy with papillary thyroid carcinoma. Vestnik stomatologii = Stomatology Bulletin. 2013;(1):61–5 (In Russ.)

9. Adramerinas M, Andreadis D, Vahtsevanos K, Poulopoulos A, Pazaitou-Panayiotou K. Sialadenitis as a complication of radioiodine therapy in patients with thyroid cancer: where do we stand? Hormones (Athens). 2021;20(4):669–78. https://doi.org/10.1007/s42000-021-00304-3

10. Erkul E, Gillespie MB. Sialendoscopy for nonstone disorders: the current evidence. Laryngoscope Investig Otolaryngol. 2016;1(5):140–5. https://doi.org/10.1002/lio2.33

11. Lee HN, An JY, Lee KM, Kim EJ, Choi WS, Kim DY. Salivary gland dysfunction after radioactive iodine (I-131) therapy in patients following total thyroidectomy: emphasis on radioactive iodine therapy dose. Clin Imaging. 2015;39(3):396–400. https://doi.org/10.1016/j.clinimag.2014.12.018

12. Lu L, Shan F, Li W, Lu H. Short-term side effects after radioiodine treatment in patients with differentiated thyroid cancer. Biomed Res Int. 2016;2016:4376720. https://doi.org/10.1155/2016/4376720

13. Van Nostrand D. Sialoadenitis secondary to ¹³¹I therapy for well-differentiated thyroid cancer. Oral Dis. 2011;17(2):154–61. https://doi.org/10.1111/j.1601-0825.2010.01726.x

14. Wu JQ, Feng HJ, Ouyang W, Sun YG, Chen P, Wang J, et al. Systematic evaluation of salivary gland damage following I-131 therapy in differentiated thyroid cancer patients by quantitative scintigraphy and clinical follow-up. Nucl Med Commun. 2015;36(8):819–26. https://doi.org/10.1097/mnm.0000000000000325

15. Ali MJ. Iodine-131 therapy and nasolacrimal duct obstructions: what we know and what we need to know. Ophthalmic Plast Reconstr Surg. 2016;32(4):243–8. https://doi.org/10.1097/iop.0000000000000647

16. Ali MJ, Vyakaranam AR, Rao JE, Prasad G, Anand Reddy PV. Iodine-131 therapy and lacrimal drainage system toxicity: nasal localization studies using whole body nuclear scintigraphy and SPECT-CT. Ophthal Plast Reconstr Surg. 2017;33(1):13–6. https://doi.org/10.1097/iop.0000000000000603

17. Fard-Esfahani A, Emami-Ardekani A, Fallahi B, Fard-Esfahani P, Beiki D, Hassanzadeh-Rad A, Eftekhari M. Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma. Nucl Med Commun. 2014;35(8):808–17. https://doi.org/10.1097/mnm.0000000000000132

18. Fedorov AA, Atkova EL, Yartsev VD. Secondary acquired nasolacrimal duct obstruction as a specific complication of treatment with radioactive iodine (morphological study). Ophthalmic Plast Reconstr Surg. 2020;36(3):250–3. https://doi.org/10.1097/iop.0000000000001521

19. Kloos RT, Duvuuri V, Jhiang SM, Cahill KV, Foster JA, Burns JA. Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. J Clin Endocrinol Metab. 2002;87(12):5817–20. https://doi.org/10.1210/jc.2002-020210

20. Yartsev VD, Solodkiy VA, Fomin DK, Borisenko TE, Atkova EL. Clinical and demographic characteristics of tearing in patients after radioiodine ablation for differentiated thyroid cancer. Curr Eye Res. 2021;46(9):1320–4. https://doi.org/10.1080/02713683.2021.1878229

21. Al-Qahtani KH, Al Asiri M, Tunio M, Aljohani NJ, Bayoumi Y, Munir I, AlAyoubi A. Nasolacrimal duct obstruction following radioactive iodine 131 therapy in differentiated thyroid cancers: review of 19 cases. Clin Ophthalmol. 2014;8:2479-2484 https://doi.org/10.2147/OPTH.S71708

22. Beldovskaya NYu, Karpishchenko SA, Baranskaya SV, Karpov AA. Lacrimal system pathology in patients with malignant thyroid tumors after radioactive iodine therapy, and its correction methods. Ophtalmologicheskie vedomosti = Ophtalmology Journal. 2017;10(4):13–7 (In Russ.) https://doi.org/10.17816/OV10413-17